Noradrenaline-and clonidine-induced inhibition of insulin release from intact and electrically permeabilized rat islets was markedly relieved by prior exposure to 100 ng of Bordetella pertussis toxin/ml. The reversal of catecholamine inhibition of insulin secretion by this toxin was not associated with a decrease in specific binding of the a2-adrenergic ligand [3H]yohimbine, and could not be fully explained by an increase in intracellular cyclic AMP. Exposure of intact islets to 1 jug of pertussis toxin/ml for 2 h, followed by electrical permeabilization and incubation with 5 1Ci of [a-32P]NAD', resulted in the ADP-ribosylation in situ of a protein of molecular mass approx. 41 kDa. These results suggest that pertussis toxin alleviates catecholamine inhibition of f-cell secretory responses by ADP-ribosylating at least one protein of molecular mass 41 kDa.
INTRODUCTION
Catecholamines inhibit insulin release from pancreatic fl-cells both in vivo (Porte & Williams, 1966; Skoglund et al., 1986 ) and in vitro (Langer et al., 1983; Tamagawa et al., 1985; Morgan & Montague, 1985) via interaction with a2-adrenergic receptors, but the resulting intracellular events that culminate in blockade of the fl-cell secretory response have yet to be fully elucidated (see Morgan, 1987) . Reported mechanisms of action include inhibition of glucose metabolism (Laychock & Bilgin, 1987) , activation of ATP-sensitive K+ channels (Ronner et al., 1988) , decreased influx of extracellular Ca21 (Skoglund et al., 1988; Nilsson et al., 1988) , modulation of prostaglandin synthesis (Metz & Robertson, 1980) and decreased cyclic AMP production (Yamazaki et al., 1982; Schuit & Pipeleers, 1986) . A family of receptor-controlled heterotrimeric guanine nucleotide-binding proteins (G proteins) are involved in stimulus-secretion coupling in a variety of cell types (Gilman, 1987) . At least one inhibitory G protein has been implicated in the transduction of the catecholamine inhibitory signal in islets (Malaisse et al., 1984; Laychock & Bilgin, 1987) . The bacterial exotoxin Bordetella pertussis toxin (PT) catalyses the ADP-ribosylation of a 41 kDa protein in many tissues (for review see Ui, 1984) , including membranes prepared from islets of Langerhans (Malaisse et al., 1984) and an insulin-secreting cell line (Vallar et al., 1987) . This 41 kDa protein is thought to be G1a, the a subunit of Gi (Malaisse et al., 1984; Dunlop & Larkins, 1986) , a G protein which negatively couples a2-adrenergic receptors to adenylate cyclase in target cells (reviewed by Exton, 1985) . Ribosylation of Giac by PT leads to the inattivation of Gi, thus preventing the transduction of inhibitory signals via this G protein.
There have been several demonstrations that prior treatment with PT can prevent adrenergic inhibition of insulin secretion in vivo or in vitro (see, e.g., Katada & Ui, 1980; Malaisse et al., 1984; Metz, 1988) . However, it has also been reported that the adrenergic inhibition of insulin secretion cannot be reversed by increasing intracellular cyclic AMP (Morgan, 1987) , suggesting that decreases in adenylate cyclase activity cannot entirely account for the inhibitory effects of catecholamines in f-cells.
In the present study we have used PT as a probe to investigate the role of islet GTP-binding proteins in noradrenaline-and clonidine-induced inhibition of insulin secretion from both intact and electrically permeabilized islets of Langerhans. We found that pretreatment of isolated islets with this toxin prevented catecholamine blockade of secretion, and this effect could be related to the ADP-ribosylation in situ of a 41 kDa protein. (Howell & Taylor, 1968) and incubated in a bicarbonate-buffered (pH 7.4) physiological salt solution (Gey & Gey, 1936) supplemented with 2 mM-glucose, 2 mM-CaCl2, 0.5 mg of bovine serum albumin/ml, 15 mM-Hepes and 100 ng of PT/ml for increasing periods of time. For incubation periods of greater than 4 h, islets were isolated under aseptic conditions in Hanks buffered salts solution, then maintained at 37°C-in tissue-culture medium 199 (pH 7.4) containing 100 jug of streptomycin/ ml, 100 units of penicillin/ml and 10 % (v/v) foetal-calf serum, in a humidified atmosphere of C02/air (1:19). Control islets were incubated, in parallel, under identical conditions, but in the absence of toxin. Insulin secretion from intact and electrically permeabilized islets
METHODS
After incubation in the absence or presence of toxin, islets were divided into two groups and used either intact or after electrical permeabilization. In experiments using intact islets, groups of three islets were incubated for 60 min at 37°C in 0.6 ml of the Gey & Gey (1936) buffer (plus 2 mm CaCl2 and 0.5 mg of albumin/ml) containing the test substances of interest. In parallel experiments islets were thoroughly washed in a K+-glutamate-based Ca2+/EGTA buffer (permeation buffer, pH 6.6), with CaCl2 added to give a free Ca2+ concentration of 50 nm (Jones et al., 1985) , then permeabilized by five exposures (each 200 #us) to an electric field (3.4 kV/cm). Such a procedure renders f-cells permeable to small molecules for at least 40 min (Yaseen et al., 1982) . Groups of ten permeabilized islets were incubated at 37°C for 30 min in 1 ml of permeation buffer containing 50 nm-or 10,uM-Ca2+ in the absence or presence of 10,UM-NA or -clonidine. Insulin secretion from both intact and permeabilized f-cells, which comprise approx. 70 % of the rat islet-cell population (Gepts, 1957) , was measured by radioimmunoassay (Jones et al., 1988 (Harper & Brooker, 1975) .
ADP-ribosylation of islet proteins in situ
Groups of 200 islets were preincubated for 2 h at 37°C , either in the absence of PT or in the presence of 1 ,g of PT/ml with or without 20 mM-3-aminobenzamide. The latter is a molecule of similar structure to nicotinamide, and it was included to decrease PT utilization of endogenous NAD+ before permeabilization of the islets and addition of labelled NAD+. After thorough washing with permeation buffer (50 nM-Ca2+, 4 C) the islets were electrically permeabilized, and then 100 islets from each group were allowed to equilibrate on ice for 15 min in 100 #1 of reaction mixture containing 5 ,Ci of [a-32P]-NAD+ in Ca2+/EGTA buffer (50 nM-Ca2"). After incubation for 30 min at 37°C, the islets were sedimented by centrifugation (9000 g, 15 s), the supernatant was removed and the reaction was stopped by addition of 20 pu1 of 'stop' buffer (10 % SDS, 500 mercaptoethanol, 5 0 glycerol, 250 mM-Tris and 0.01 00 Bromophenol Blue) and boiling for 3 min. Proteins were separated by electrophoresis on a SDS/10 %-polyacrylamide gel, and incorporated 32P radioactivity was detected by autoradiography with X-omat SR film. The approximate molecular masses of radiolabelled proteins were estimated by comparison with the migration positions of proteins of known molecular masses. Yohimbine binding to islets
Binding of [3H]yohimbine (87 Ci/mmol) to cultured intact islets was determined by a modification of the method of Fyles et al. (1987) . Groups of 100 islets were incubated at 22°C in 100 #1 of 10 mM-Tris/275 mMsucrose buffer (pH 7.4) containing either 50 jtM-ascorbic acid or 1O /tM-idazoxan in the presence of 50 nm-[3H]yohimbine. After 15 min islets were transferred to nylon mesh filters (0.1 ,um pore size), washed with 30 ml of the ice-cold Tris/sucrose buffer (pH 7.4) at a flow rate of approx. 180 ml/min, then solubilized in 2 M-HClO4. After addition of 12 ml of scintillant, [3H]yohimbine remaining bound to islets was measured in a Beckman LS 7500 liquid-scintillation counter.
Statistical analysis
All results are expressed as means + S.E.M. Differences between means were analysed by Student's paired or unpaired t tests, as appropriate, and considered significant when P < 0.05.
RESULTS

Effect of PT treatment on insulin release from intact islets
Both control and toxin-treated intact islets responded to an elevation in glucose concentration from 2 mm to 20 mm with an increased rate of insulin release, although toxin-treated islets consistently showed a higher secretory rate at 20 mM-glucose (Table 1) . At 10 lim, NA and clonidine fully suppressed glucose-induced insulin release from islets incubated in the absence of PT (P < 0.01 versus 20 mM-glucose for both catecholamines). The inhibitory effects of clonidine (10 gM) on glucosestimulated insulin secretion were reversed by treatment with PT, in a manner dependent on the time of incubation with the toxin (Fig. 1 ). Thus the inhibition by clonidine diminished with increased exposure time to the toxin, and after a preincubation period of 16 h the secretory response to 20 mM-glucose had been completely restored.
A similar time-dependent reversal of the inhibition by NA was observed in intact islets, but NA was still able to exert a partial blockade of secretion (in three of the six experiments) even after islets had been cultured with toxin for 20 h.
Effect of PT treatment on Ca2"-induced insulin secretion from electrically permeabilized islets Increasing the free Ca2" concentration of the permeation buffer from 50 nm to 1O /UM resulted in a 2-fold increase in insulin release from control and toxin-treated permeabilized islets. Culturing islets with 100 ng of PT/ ml for 20 h did not significantly alter secretion from permeabilized islets in response to either 50 nm-or 10 ftMCa21 (Figs. 2a and 3a) . At 1O /Lm, NA significantly (P < 0.005), but incompletely, inhibited 10 ,M-Ca2+-Vol. 258 X, islets exposed to 100 ng of PT/ml for 24 h. Significance by paired t tests: *P < 0.005 versus control 10 ,#M-Ca2 .
induced insulin release from islets permeabilized after culture for 20 h in the absence of PT (Fig. 2b) . PT-treated Comparable results were observed with 10 gM-clonidine (Figs. 3a and 3b) . treatment also elevated basal cyclic AMP concentrations (P < 0.001), without affecting cyclic AMP accumulation at 20 mM-glucose. However, although NA always suppressed insulin release from control islets, this was not always coupled to a decrease in cellular cyclic AMP generation; overall, NA was without significant effect on cyclic AMP concentrations (20 mM-glucose, 27.0 + 1.9 fmol/islet; + 10 1tM-NA, 27.9 + 3.4; means + S.E.M., n = 16-17, P > 0.5).
Effect of PT on protein ribosylation
Preincubation of islets with PT (1 ,tg/ml) followed by electrical permeabilization and incubation in the presence of [a-32P]NAD+ resulted in ADP-ribosylation in situ of a protein of molecular mass approx. 41 kDa (Fig. 4, lane  2) . Islets incubated in the absence of the toxin showed no incorporation of radiolabel into this protein (lane 1). Supplementing the preincubation buffer with 20 mM-3-aminobenzamide did not appear to increase the labelling of the 41 kDa band, nor the number of proteins which incorporated the label (lane 3). I3HIYohimbine binding to islets after PT treatment The concentration of yohimbine-binding sites was not significantly altered by culturing islets in the presence of PT (100 ng/ml) for 24 h, assuming the existence of a single population of high-affinity binding sites for yohimbine in islets . Thus 286 + 25 fmol of yohimbine-binding sites/mg of islet protein were observed in controls, compared with 279+45 in PT-treated islets (means+S.E.M., n = 4, P>0.5).
Effects of PT treatment on intracellular cyclic AMP concentrations Clonidine inhibition of insulin secretion was consistently associated with a decrease in cyclic AMP concentrations (P < 0.001 versus 20 mM-glucose), and this too was relieved by PT pretreatment (Table 2) . Toxin 
DISCUSSION
In this study we have investigated the mechanism of action of adrenergic inhibition of insulin secretion by using PT, which prevents the inhibitory effects of catecholamines on pancreatic f-cells (Katada & Ui, 1980) . PT ing ADP-ribosylation of specific G proteins, including transducin (Van Dop et al., 1984) , G., a protein of unknown function prevalent in the brain (Neer et al., 1984) , and Gi . A substrate for PT of molecular mass approx. 41 kDa has previously been detected in islet membranes and tentatively identified as Gi (Malaisse et al., 1984; Dunlop & Larkins, 1986) . ADPribosylation of Gi by PT results in its uncoupling from the activated receptor and stabilization in the inactive GDP-bound form, thus preventing receptor-mediated inhibition of adenylate cyclase activity (Spiegel, 1987 (Yajima et al., 1978; Malaisse et al., 1984; Metz, 1988) or in vitro (Katada & Ui, 1980) . In the present study, incubation of isolated islets in the presence of PT caused a time-dependent reversal of adrenergic suppression of glucose-induced insulin release. The lack of effect of the toxin during incubation periods of I h is consistent with previous observations in islets that there is an initial lag period before toxin effects are detectable (Katada & Ui, 1980) , presumably a reflection of the time taken by the toxin to traverse the f-cell plasma membrane.
Catecholamines also inhibit insulin secretion in response to increased intracellular Ca2l in K+-depolarized intact #-cells (Nilsson et al., 1988; Metz, 1988) , digitonin-permeabilized islets (Tamagawa et al., 1985) and electrically permeabilized islets (Jones et al., 1987) . In the present study we found a significant, but incomplete, inhibition of Ca2l-induced insulin secretion from electrically permeabilized islets, which was fully relieved by treating islets with PT before permeabilization.
There are a number of possible mechanisms by which PT may desensitize f-cells to adrenergic agonists. Our studies suggest that the effects of PT are not simply caused by a decrease in binding sites for catecholamines, since toxin treatment had no effect on specific binding of yohimbine, an z2-specific antagonist, to islets.
An alternative explanation is that PT works by uncoupling inhibitory adrenergic receptors from adenylate cyclase, thus preventing adrenergic agonists from decreasing intracellular cyclic AMP (Exton, 1985) . In our experiments, PT had detectable effects on cellular concentrations ofcyclic AMP. Thus treatment with PT increased the cyclic AMP content of unstimulated islets, perhaps indicating that ADP-ribosylation of G, had relieved a tonic inhibition of adenylate cyclase. However, the increases in glucose-induced insulin secretion from toxintreated islets were not accompanied by detectable increases in cyclic AMP content, nor could they be explained by increases in insulin content, since islets exposed to PT contained the same amount of insulin as did control islets (results not shown). Similar enhancements of glucose-stimulated insulin secretion after pertussis-vaccine treatment in vivo (Katada & Ui, 1978; Smith & Furman, 1988) or PT treatment in vitro (Katada & Ui, 1980; Dunlop & Larkins, 1983; Smith & Furman, 1988) have been reported, but the manner by which secretion is increased is not clear.
Despite these effects of PT on cyclic AMP content, we were unable to correlate consistently catecholamine effects on cyclic AMP with effects on insulin secretion.
Thus the inhibition of insulin release from control islets by clonidine, an a2-specific agonist, was accompanied by decreases in intracellular cyclic AMP. These effects were prevented by treating the islets with PT before exposure to clonidine, implying that the effects of clonidine on intracellular cyclic AMP were mediated through G1. In contrast, the inhibitory effects of NA on insulin secretion were not invariably coupled to a decrease in cellular cyclic AMP, and in some instances were accompanied by increases in cyclic AMP. A stimulation of cyclic AMP production in parallel with an inhibition of insulin secretion by adrenaline has been previously described (Ullrich & Wollheim, 1984) , and was probably secondary to activation of islet f,-adrenergic receptors. Previous studies in intact (Nakaki et al., 1983; Morgan & Montague, 1985; Metz, 1988) and permeabilized (Tamagawa et al., 1985; Jones et al., 1987) islets suggest that inhibition of adenylate cyclase is not the sole mechanism of catecholamine action, since increasing intracellular cyclic AMP does not reverse catecholamine inhibition of insulin secretion (for review see Morgan, 1987 These results allow several tentative conclusions to be drawn. First, PT can relieve adrenergic inhibition of both glucose-induced insulin secretion from intact islets and Ca2"-induced secretion from permeabilized islets. Secondly, the adrenergic inhibition of insulin release can be dissociated from inhibitory effects on adenylate cyclase which are mediated by Gi. The relief of adrenergic inhibition of secretion by PT cannot therefore be wholly attributed to the ribosylation and inactivation of adenylate cyclase-associated Gi.
If the effects of PT in pancreatic islets are mediated solely by ribosylation of G proteins, as they appear to be (for review see Ui, 1984) , then either Gi is coupled to an effector system other than adenylate cyclase, or another G protein is involved in the transduction of a2-adrenergic signals in ,-cells. Neither our experiments, nor studies by others (Malaisse et al., 1984; Dunlop & Larkins, 1986; Vallar et al., 1987) , demonstrated PT-dependent ribosylation of a G protein other than Gi, using onedimensional protein-separation techniques. However, these results do not preclude the existence of another substrate which has a similar molecular mass to Gi, or which is a minor ribosylated component in fl-cells compared with Gi.
Several alternative mechanisms for transduction of adrenergic signals in f-cells, other than by G1-mediated inhibition of adenylate cyclase, have been suggested. For example, glucose and other nutrient secretagogues stimulate insulin secretion after their metabolism by f-cells (see Prentki & Matchinsky, 1987) , and catecholamines could therefore inhibit insulin secretion through effects on glucose metabolism. It has been reported that a2-agonists inhibit glucose utilization by isolated rat islets, an effect which can be blocked by pretreatment of the islets with PT (Laychock & Bilgin, 1987) . The identity of the PT substrate was not investigated, but it appeared not to be adenylate cyclase-linked Gi since analogues of cyclic AMP did not reverse the inhibitory actions of a2-agonists (Laychock & Bilgin, 1987) . Although this effect may be important in the adrenergic inhibition of glucoseinduced insulin secretion from intact islets, it is unlikely to be the only mechanism, since catecholamines inhibit, in a PT-reversible manner, Ca2+-induced secretion from permeabilized islets which do not retain the capacity to metabolize or respond to glucose (Pedley et al., 1986; Wolf et al., 1988) .
Similarly, a2-agonists have been reported to modify fluxes of Ca21 (Skoglund et al., 1988; Nilsson et al., 1988) or K+ (Ronner et al., 1988) Morgan & Montague, 1985; Skoglund et al., 1988; Nilsson et al., 1988; Metz, 1988) , but such effects cannot be the sole mechanism of action ofcatecholamines, since they are unable to account for inhibition of insulin secretion for permeabilized islets in which membrane potentials are collapsed and intracellular Ca21 concentrations regulated by chelating buffers.
Several unidentified G proteins have been implicated in other signal-transduction systems in islets, but are unlikely to be involved in adrenergic inhibition of insulin secretion, since they appear to be insensitive to PT. Thus the hydrolysis of membrane phosphoinositides, which may play an important role in the regulation of insulin secretion (see Prentki & Matschinsky, 1987) , is thought to be regulated by a G protein (Vallar et al., 1987) , but neither oc2-agonists nor PT modify phosphoinositide hydrolysis in islets (Morgan & Montague, 1985; Dunlop & Larkins, 1986; Blachier et al., 1987) or in an insulinsecreting cell line (Vallar et al., 1987) . The involvement of yet another G protein, functionally distinct from adenylate cyclase-or phospholipase-associated G protein(s), in the control of insulin secretion has been proposed (Vallar et al., 1987) . Again, this putative G protein is not PT-sensitive (Vallar et al., 1987) , and so cannot account for adrenergic inhibition of insulin secretion, nor its reversal by PT.
A feasible mechanism of adrenergic inhibition of insulin secretion could be through regulation of arachidonic acid metabolites. Metz (1988) has pointed out the similarities between inhibition of insulin secretion by adrenaline and that caused by lipoxygenase inhibitors, and there is evidence that a PT-sensitive G protein linked to phospholipase A9, which generates arachidonic acid, is present in human platelets (Fuse & Tai, 1987) . However, the association between a2-adrenergic receptors, phospholipase A2 activity, arachidonic acid metabolites and the inhibition of insulin secretion is still largely circumstantial. Further studies are required to determine the precise role, if any, of arachidonic acid metabolites in the control of insulin secretion and the transduction of adrenergic signals in pancreatic f-cells.
In conclusion, this study has demonstrated that PT treatment prevents a2-adrenergic inhibition of glucoseinduced insulin secretion from intact islets and Ca2+-induced secretion from electrically permeabilized islets. The sensitivity to PT of the inhibition of secretion from both intact and permeabilized islets suggests a common pathway of catecholamine action in the two experimental models, which cannot be fully accounted for by Gimediated effects on adenylate cyclase. These results suggest that the adrenergic inhibition of secretion involves either Gi, or another PT-sensitive G protein, in a signal-transduction system distinct from inhibition of adenylate cyclase.
